Intermittent versus maintenance iron therapy in children on hemodialysis: a randomized study View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2003-11-22

AUTHORS

Ma de la Cruz Ruiz-Jaramillo, Juan Manuel Guízar-Mendoza, María de Jesús Gutiérrez-Navarro, Luis Antonio Dubey-Ortega, Norma Amador-Licona

ABSTRACT

In patients with renal anemia, iron therapy can be administered intermittently or regularly at a low dose. We performed a randomized clinical trial in pediatric patients with end-stage renal failure on hemodialysis and absolute or functional iron deficiency. The study group received maintenance iron therapy according to the ferritin serum levels and the control group received intermittent 10-weekly doses. Success was defined as stabilization of ferritin levels between 100 and 800 μg/l and transferrin saturation (TSAT) between 20% and 50%, in addition to an increase in the hemoglobin level. The major reason for exclusion was iron overload. The study group received 6 mg/kg per month of parenteral iron [95% confidence interval (CI) 3.3–8.8] and the control group 14.4 mg/kg per month (95% CI 12–16.8) (P<0.001). After 4 months of treatment, ferritin levels increased to 66 μg/l (95% CI 69–200) in the study group and to 334 μg/l (95% CI 145–522) in the control group (P=0.009). Maintenance therapy and intermittent weekly doses were successful in 73% and 38%, respectively. After 3 months of treatment, hemoglobin levels increased to 10 g/dl, with no difference between the groups. However, in the control group the increase in hemoglobin levels was unsustained, and 3 patients needed transfusion. Patients in the control group had a higher risk of iron overload than patients in the study group (70% vs. 19%). Thus, the regimen based on assessment of serum ferritin levels was more efficient than the intermittent regimen because it increased and maintained the hemoglobin levels with lower iron doses and a lower risk of iron overload. More... »

PAGES

77-81

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00467-003-1288-9

DOI

http://dx.doi.org/10.1007/s00467-003-1288-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1050040500

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/14634860


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anemia, Iron-Deficiency", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ferritins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hemoglobins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Iron", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kidney Failure, Chronic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transferrin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Honda de San Miguel 544 CP 37390, Le\u00f3n, Gto. M\u00e9xico", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Mexican Institute of Social Security, Le\u00f3n, M\u00e9xico", 
            "Honda de San Miguel 544 CP 37390, Le\u00f3n, Gto. M\u00e9xico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ruiz-Jaramillo", 
        "givenName": "Ma de la Cruz", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mexican Institute of Social Security, Le\u00f3n, M\u00e9xico", 
          "id": "http://www.grid.ac/institutes/grid.419157.f", 
          "name": [
            "Mexican Institute of Social Security, Le\u00f3n, M\u00e9xico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gu\u00edzar-Mendoza", 
        "givenName": "Juan Manuel", 
        "id": "sg:person.0764236140.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0764236140.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mexican Institute of Social Security, Le\u00f3n, M\u00e9xico", 
          "id": "http://www.grid.ac/institutes/grid.419157.f", 
          "name": [
            "Mexican Institute of Social Security, Le\u00f3n, M\u00e9xico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Guti\u00e9rrez-Navarro", 
        "givenName": "Mar\u00eda de Jes\u00fas", 
        "id": "sg:person.01351405054.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351405054.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mexican Institute of Social Security, Le\u00f3n, M\u00e9xico", 
          "id": "http://www.grid.ac/institutes/grid.419157.f", 
          "name": [
            "Mexican Institute of Social Security, Le\u00f3n, M\u00e9xico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dubey-Ortega", 
        "givenName": "Luis Antonio", 
        "id": "sg:person.01015016250.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01015016250.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mexican Institute of Social Security, Le\u00f3n, M\u00e9xico", 
          "id": "http://www.grid.ac/institutes/grid.419157.f", 
          "name": [
            "Mexican Institute of Social Security, Le\u00f3n, M\u00e9xico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Amador-Licona", 
        "givenName": "Norma", 
        "id": "sg:person.0650007540.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0650007540.19"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s004670100645", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008500816", 
          "https://doi.org/10.1007/s004670100645"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1203/00006450-199904020-01970", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064216175", 
          "https://doi.org/10.1203/00006450-199904020-01970"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s004670050747", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029290964", 
          "https://doi.org/10.1007/s004670050747"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2003-11-22", 
    "datePublishedReg": "2003-11-22", 
    "description": "In patients with renal anemia, iron therapy can be administered intermittently or regularly at a low dose. We performed a randomized clinical trial in pediatric patients with end-stage renal failure on hemodialysis and absolute or functional iron deficiency. The study group received maintenance iron therapy according to the ferritin serum levels and the control group received intermittent 10-weekly doses. Success was defined as stabilization of ferritin levels between 100 and 800\u00a0\u03bcg/l and transferrin saturation (TSAT) between 20% and 50%, in addition to an increase in the hemoglobin level. The major reason for exclusion was iron overload. The study group received 6\u00a0mg/kg per month of parenteral iron [95% confidence interval (CI) 3.3\u20138.8] and the control group 14.4\u00a0mg/kg per month (95% CI 12\u201316.8) (P<0.001). After 4\u00a0months of treatment, ferritin levels increased to 66\u00a0\u03bcg/l (95% CI 69\u2013200) in the study group and to 334\u00a0\u03bcg/l (95% CI 145\u2013522) in the control group (P=0.009). Maintenance therapy and intermittent weekly doses were successful in 73% and 38%, respectively. After 3\u00a0months of treatment, hemoglobin levels increased to 10\u00a0g/dl, with no difference between the groups. However, in the control group the increase in hemoglobin levels was unsustained, and 3 patients needed transfusion. Patients in the control group had a higher risk of iron overload than patients in the study group (70% vs. 19%). Thus, the regimen based on assessment of serum ferritin levels was more efficient than the intermittent regimen because it increased and maintained the hemoglobin levels with lower iron doses and a lower risk of iron overload.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00467-003-1288-9", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1097267", 
        "issn": [
          "0931-041X", 
          "1432-198X"
        ], 
        "name": "Pediatric Nephrology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "keywords": [
      "maintenance iron therapy", 
      "months of treatment", 
      "hemoglobin levels", 
      "study group", 
      "iron therapy", 
      "ferritin levels", 
      "control group", 
      "iron overload", 
      "transferrin saturation", 
      "end-stage renal failure", 
      "ferritin serum levels", 
      "low iron doses", 
      "functional iron deficiency", 
      "randomized clinical trials", 
      "serum ferritin levels", 
      "maintenance therapy", 
      "renal failure", 
      "weekly doses", 
      "pediatric patients", 
      "intermittent regimen", 
      "serum levels", 
      "renal anemia", 
      "parenteral iron", 
      "clinical trials", 
      "low dose", 
      "high risk", 
      "lower risk", 
      "patients", 
      "iron doses", 
      "therapy", 
      "iron deficiency", 
      "months", 
      "doses", 
      "regimen", 
      "hemodialysis", 
      "overload", 
      "treatment", 
      "risk", 
      "group", 
      "transfusion", 
      "levels", 
      "anemia", 
      "dl", 
      "dose", 
      "trials", 
      "major reason", 
      "children", 
      "increase", 
      "deficiency", 
      "failure", 
      "assessment", 
      "differences", 
      "study", 
      "exclusion", 
      "addition", 
      "reasons", 
      "success", 
      "saturation", 
      "stabilization", 
      "iron", 
      "control group 14.4", 
      "group 14.4", 
      "intermittent weekly doses"
    ], 
    "name": "Intermittent versus maintenance iron therapy in children on hemodialysis: a randomized study", 
    "pagination": "77-81", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1050040500"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00467-003-1288-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "14634860"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00467-003-1288-9", 
      "https://app.dimensions.ai/details/publication/pub.1050040500"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:15", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_376.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00467-003-1288-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00467-003-1288-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00467-003-1288-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00467-003-1288-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00467-003-1288-9'


 

This table displays all metadata directly associated to this object as RDF triples.

224 TRIPLES      22 PREDICATES      106 URIs      95 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00467-003-1288-9 schema:about N1357d957c0074e5c9cfcbc2c9f43bf6f
2 N2c0bff223bee478b93eb1a263934a713
3 N4c3803b7cc54441399e3b432c0d021b0
4 N55e18eab014345229b6348fcde4eb5b6
5 N595526517c5c4afbbcbcb82d0afbbc68
6 N7191b4f33091498eab23f5f05eb54f20
7 N8bb9e38ddb0c44d79cdeec3d0514d12c
8 N90c39a2dc5654ff7b28c9717745c5d21
9 N9430c8436be84fccb36971273c345105
10 Na5e0d182461449c1ae16e0ab2177187d
11 Nae5e9111af074f84b4163a40ac5d9af7
12 Nc7571a8e72904fe292b81b4355afd532
13 Ne0c69fb6eeee4f459ad0db067687a400
14 Nfcecd0a46f624490a10a628f6e4ddad2
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author Nb6b0135da8464c79914407e3e4d9c996
18 schema:citation sg:pub.10.1007/s004670050747
19 sg:pub.10.1007/s004670100645
20 sg:pub.10.1203/00006450-199904020-01970
21 schema:datePublished 2003-11-22
22 schema:datePublishedReg 2003-11-22
23 schema:description In patients with renal anemia, iron therapy can be administered intermittently or regularly at a low dose. We performed a randomized clinical trial in pediatric patients with end-stage renal failure on hemodialysis and absolute or functional iron deficiency. The study group received maintenance iron therapy according to the ferritin serum levels and the control group received intermittent 10-weekly doses. Success was defined as stabilization of ferritin levels between 100 and 800 μg/l and transferrin saturation (TSAT) between 20% and 50%, in addition to an increase in the hemoglobin level. The major reason for exclusion was iron overload. The study group received 6 mg/kg per month of parenteral iron [95% confidence interval (CI) 3.3–8.8] and the control group 14.4 mg/kg per month (95% CI 12–16.8) (P<0.001). After 4 months of treatment, ferritin levels increased to 66 μg/l (95% CI 69–200) in the study group and to 334 μg/l (95% CI 145–522) in the control group (P=0.009). Maintenance therapy and intermittent weekly doses were successful in 73% and 38%, respectively. After 3 months of treatment, hemoglobin levels increased to 10 g/dl, with no difference between the groups. However, in the control group the increase in hemoglobin levels was unsustained, and 3 patients needed transfusion. Patients in the control group had a higher risk of iron overload than patients in the study group (70% vs. 19%). Thus, the regimen based on assessment of serum ferritin levels was more efficient than the intermittent regimen because it increased and maintained the hemoglobin levels with lower iron doses and a lower risk of iron overload.
24 schema:genre article
25 schema:inLanguage en
26 schema:isAccessibleForFree false
27 schema:isPartOf N8e22d202896644ed8ed286149650e0b8
28 Nb8f1011128a243d0b807bdefa02ffb1c
29 sg:journal.1097267
30 schema:keywords addition
31 anemia
32 assessment
33 children
34 clinical trials
35 control group
36 control group 14.4
37 deficiency
38 differences
39 dl
40 dose
41 doses
42 end-stage renal failure
43 exclusion
44 failure
45 ferritin levels
46 ferritin serum levels
47 functional iron deficiency
48 group
49 group 14.4
50 hemodialysis
51 hemoglobin levels
52 high risk
53 increase
54 intermittent regimen
55 intermittent weekly doses
56 iron
57 iron deficiency
58 iron doses
59 iron overload
60 iron therapy
61 levels
62 low dose
63 low iron doses
64 lower risk
65 maintenance iron therapy
66 maintenance therapy
67 major reason
68 months
69 months of treatment
70 overload
71 parenteral iron
72 patients
73 pediatric patients
74 randomized clinical trials
75 reasons
76 regimen
77 renal anemia
78 renal failure
79 risk
80 saturation
81 serum ferritin levels
82 serum levels
83 stabilization
84 study
85 study group
86 success
87 therapy
88 transferrin saturation
89 transfusion
90 treatment
91 trials
92 weekly doses
93 schema:name Intermittent versus maintenance iron therapy in children on hemodialysis: a randomized study
94 schema:pagination 77-81
95 schema:productId N4b8c4716f64f462c966265fd7201c3ee
96 Nc6f85ad4b508472eb840323e494a9826
97 Nfbfd27683ea742558cc1f6eb25d51100
98 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050040500
99 https://doi.org/10.1007/s00467-003-1288-9
100 schema:sdDatePublished 2021-12-01T19:15
101 schema:sdLicense https://scigraph.springernature.com/explorer/license/
102 schema:sdPublisher N528bfd96dcd946d2bcef664c68a16b2c
103 schema:url https://doi.org/10.1007/s00467-003-1288-9
104 sgo:license sg:explorer/license/
105 sgo:sdDataset articles
106 rdf:type schema:ScholarlyArticle
107 N1357d957c0074e5c9cfcbc2c9f43bf6f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Ferritins
109 rdf:type schema:DefinedTerm
110 N143dad2a691541ff90c70b23f8ac1360 rdf:first sg:person.01015016250.14
111 rdf:rest Ne2b1ade62d5e4a7b9a78268206323641
112 N2c0bff223bee478b93eb1a263934a713 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Anemia, Iron-Deficiency
114 rdf:type schema:DefinedTerm
115 N4b8c4716f64f462c966265fd7201c3ee schema:name dimensions_id
116 schema:value pub.1050040500
117 rdf:type schema:PropertyValue
118 N4c3803b7cc54441399e3b432c0d021b0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Transferrin
120 rdf:type schema:DefinedTerm
121 N528bfd96dcd946d2bcef664c68a16b2c schema:name Springer Nature - SN SciGraph project
122 rdf:type schema:Organization
123 N55e18eab014345229b6348fcde4eb5b6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Treatment Outcome
125 rdf:type schema:DefinedTerm
126 N595526517c5c4afbbcbcb82d0afbbc68 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Humans
128 rdf:type schema:DefinedTerm
129 N7191b4f33091498eab23f5f05eb54f20 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Iron
131 rdf:type schema:DefinedTerm
132 N8bb9e38ddb0c44d79cdeec3d0514d12c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Drug Administration Schedule
134 rdf:type schema:DefinedTerm
135 N8e22d202896644ed8ed286149650e0b8 schema:volumeNumber 19
136 rdf:type schema:PublicationVolume
137 N90c39a2dc5654ff7b28c9717745c5d21 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Male
139 rdf:type schema:DefinedTerm
140 N9430c8436be84fccb36971273c345105 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Female
142 rdf:type schema:DefinedTerm
143 Na5e0d182461449c1ae16e0ab2177187d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Kidney Failure, Chronic
145 rdf:type schema:DefinedTerm
146 Nae5e9111af074f84b4163a40ac5d9af7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Child
148 rdf:type schema:DefinedTerm
149 Nb6b0135da8464c79914407e3e4d9c996 rdf:first Nbb1b911111a649cda23194f06af1418d
150 rdf:rest Nfa6f41628f9a473c9bae2842e4962816
151 Nb8f1011128a243d0b807bdefa02ffb1c schema:issueNumber 1
152 rdf:type schema:PublicationIssue
153 Nba336d9828e5486db6a04909b47b2b1e rdf:first sg:person.01351405054.27
154 rdf:rest N143dad2a691541ff90c70b23f8ac1360
155 Nbb1b911111a649cda23194f06af1418d schema:affiliation grid-institutes:None
156 schema:familyName Ruiz-Jaramillo
157 schema:givenName Ma de la Cruz
158 rdf:type schema:Person
159 Nc6f85ad4b508472eb840323e494a9826 schema:name pubmed_id
160 schema:value 14634860
161 rdf:type schema:PropertyValue
162 Nc7571a8e72904fe292b81b4355afd532 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Injections, Intravenous
164 rdf:type schema:DefinedTerm
165 Ne0c69fb6eeee4f459ad0db067687a400 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Hemoglobins
167 rdf:type schema:DefinedTerm
168 Ne2b1ade62d5e4a7b9a78268206323641 rdf:first sg:person.0650007540.19
169 rdf:rest rdf:nil
170 Nfa6f41628f9a473c9bae2842e4962816 rdf:first sg:person.0764236140.65
171 rdf:rest Nba336d9828e5486db6a04909b47b2b1e
172 Nfbfd27683ea742558cc1f6eb25d51100 schema:name doi
173 schema:value 10.1007/s00467-003-1288-9
174 rdf:type schema:PropertyValue
175 Nfcecd0a46f624490a10a628f6e4ddad2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Adolescent
177 rdf:type schema:DefinedTerm
178 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
179 schema:name Medical and Health Sciences
180 rdf:type schema:DefinedTerm
181 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
182 schema:name Clinical Sciences
183 rdf:type schema:DefinedTerm
184 sg:journal.1097267 schema:issn 0931-041X
185 1432-198X
186 schema:name Pediatric Nephrology
187 schema:publisher Springer Nature
188 rdf:type schema:Periodical
189 sg:person.01015016250.14 schema:affiliation grid-institutes:grid.419157.f
190 schema:familyName Dubey-Ortega
191 schema:givenName Luis Antonio
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01015016250.14
193 rdf:type schema:Person
194 sg:person.01351405054.27 schema:affiliation grid-institutes:grid.419157.f
195 schema:familyName Gutiérrez-Navarro
196 schema:givenName María de Jesús
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351405054.27
198 rdf:type schema:Person
199 sg:person.0650007540.19 schema:affiliation grid-institutes:grid.419157.f
200 schema:familyName Amador-Licona
201 schema:givenName Norma
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0650007540.19
203 rdf:type schema:Person
204 sg:person.0764236140.65 schema:affiliation grid-institutes:grid.419157.f
205 schema:familyName Guízar-Mendoza
206 schema:givenName Juan Manuel
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0764236140.65
208 rdf:type schema:Person
209 sg:pub.10.1007/s004670050747 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029290964
210 https://doi.org/10.1007/s004670050747
211 rdf:type schema:CreativeWork
212 sg:pub.10.1007/s004670100645 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008500816
213 https://doi.org/10.1007/s004670100645
214 rdf:type schema:CreativeWork
215 sg:pub.10.1203/00006450-199904020-01970 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064216175
216 https://doi.org/10.1203/00006450-199904020-01970
217 rdf:type schema:CreativeWork
218 grid-institutes:None schema:alternateName Honda de San Miguel 544 CP 37390, León, Gto. México
219 schema:name Honda de San Miguel 544 CP 37390, León, Gto. México
220 Mexican Institute of Social Security, León, México
221 rdf:type schema:Organization
222 grid-institutes:grid.419157.f schema:alternateName Mexican Institute of Social Security, León, México
223 schema:name Mexican Institute of Social Security, León, México
224 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...